Drug Profile
Cyclobenzaprine hydrochloride very low dose - Tonix Pharmaceuticals
Alternative Names: Cyclobenzaprine HCL; cyclobenzaprine HCl sublingual tablets; Cyclobenzaprine hydrochloride - Tonix Pharmaceuticals; KRL-102; TNX-102; TNX-102 SL; Tonmya; VLD-cyclobenzaprineLatest Information Update: 08 Apr 2024
Price :
$50
*
At a glance
- Originator Vela Pharmaceuticals
- Developer Tonix Pharmaceuticals Holding Corp; Tonix Pharmaceuticals Inc
- Class Amines; Analgesics; Anxiolytics; Behavioural disorder therapies; Dibenzocycloheptenes; Drug withdrawal therapies; Muscle relaxants; Small molecules
- Mechanism of Action Alpha 1 adrenergic receptor antagonists; Histamine H1 receptor antagonists; Muscarinic M1 receptor antagonists; Serotonin 2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Fibromyalgia; Post-traumatic stress disorders
- Phase II Agitation; Post acute COVID 19 syndrome
- No development reported Alcoholism; Unspecified
Most Recent Events
- 01 Apr 2024 Tonix Pharmaceuticals plans the phase II OASIS trial in Post-traumatic stress disorder in USA (Sublingual) in second quarter of 2024
- 28 Mar 2024 Tonix Pharmaceuticals announces intention to submit NDA to US FDA for Fibromyalgia (Sublingual) in the second half of 2024
- 11 Mar 2024 Efficacy data from the phase III RESILIENT trial in Fibromyalgia released by Tonix Pharmaceuticals